M&A Deal Summary

Nichi-Iko Pharmaceutical Acquires Sagent Pharmaceuticals

On July 11, 2016, Nichi-Iko Pharmaceutical acquired life science company Sagent Pharmaceuticals for 736M USD

Acquisition Highlights
  • This is Nichi-Iko Pharmaceutical’s 1st transaction in the Life Science sector.
  • This is Nichi-Iko Pharmaceutical’s largest (disclosed) transaction.
  • This is Nichi-Iko Pharmaceutical’s 1st transaction in the United States.
  • This is Nichi-Iko Pharmaceutical’s 1st transaction in Illinois.

M&A Deal Summary
Date 2016-07-11
Target Sagent Pharmaceuticals
Sector Life Science
Buyer(s) Nichi-Iko Pharmaceutical
Deal Type Add-on Acquisition
Deal Value 736M USD
Advisor(s) Perella Weinberg Partners
Morgan Stanley (Financial)
Kirkland & Ellis (Legal)

Target

Sagent Pharmaceuticals

Schaumburg, Illinois, United States
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products with a specific emphasis on injectables.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nichi-Iko Pharmaceutical

Toyama, Japan
Category Company
Founded 1965
Sector Medical Products
Employees2,725
Revenue 179.1B JPY (2022)
DESCRIPTION

Nichi-Iko Pharmaceutical is a generic drug manufacturer. It has grown market share with an extensive lineup of more than 1,000 commercialized products. Nichi-Iko Pharmaceutical was founded in 1965 and is based in Toyama, Japan.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Illinois) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal